Cargando…

Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions

Background: The objective of this study was to assess the safety and performance of the Omnipod(®) personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an investigational device. Materia...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherr, Jennifer L., Buckingham, Bruce A., Forlenza, Gregory P., Galderisi, Alfonso, Ekhlaspour, Laya, Wadwa, R. Paul, Carria, Lori, Hsu, Liana, Berget, Cari, Peyser, Thomas A., Lee, Joon Bok, O'Connor, Jason, Dumais, Bonnie, Huyett, Lauren M., Layne, Jennifer E., Ly, Trang T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047109/
https://www.ncbi.nlm.nih.gov/pubmed/31596130
http://dx.doi.org/10.1089/dia.2019.0286
_version_ 1783502076468264960
author Sherr, Jennifer L.
Buckingham, Bruce A.
Forlenza, Gregory P.
Galderisi, Alfonso
Ekhlaspour, Laya
Wadwa, R. Paul
Carria, Lori
Hsu, Liana
Berget, Cari
Peyser, Thomas A.
Lee, Joon Bok
O'Connor, Jason
Dumais, Bonnie
Huyett, Lauren M.
Layne, Jennifer E.
Ly, Trang T.
author_facet Sherr, Jennifer L.
Buckingham, Bruce A.
Forlenza, Gregory P.
Galderisi, Alfonso
Ekhlaspour, Laya
Wadwa, R. Paul
Carria, Lori
Hsu, Liana
Berget, Cari
Peyser, Thomas A.
Lee, Joon Bok
O'Connor, Jason
Dumais, Bonnie
Huyett, Lauren M.
Layne, Jennifer E.
Ly, Trang T.
author_sort Sherr, Jennifer L.
collection PubMed
description Background: The objective of this study was to assess the safety and performance of the Omnipod(®) personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an investigational device. Materials and Methods: A 96-h hybrid closed-loop (HCL) study was conducted in a supervised hotel/rental home setting following a 7-day outpatient standard therapy (ST) phase. Eligible participants were aged 6–65 years with A1C <10.0% using insulin pump therapy or multiple daily injections. Meals during HCL were unrestricted, with boluses administered per usual routine. There was daily physical activity. The primary endpoints were percentage of time with sensor glucose <70 and ≥250 mg/dL. Results: Participants were 11 adults, 10 adolescents, and 15 children aged (mean ± standard deviation) 28.8 ± 7.9, 14.3 ± 1.3, and 9.9 ± 1.0 years, respectively. Percentage time ≥250 mg/dL during HCL was 4.5% ± 4.2%, 3.5% ± 5.0%, and 8.6% ± 8.8% per respective age group, a 1.6-, 3.4-, and 2.0-fold reduction compared to ST (P = 0.1, P = 0.02, and P = 0.03). Percentage time <70 mg/dL during HCL was 1.9% ± 1.3%, 2.5% ± 2.0%, and 2.2% ± 1.9%, a statistically significant decrease in adults when compared to ST (P = 0.005, P = 0.3, and P = 0.3). Percentage time 70–180 mg/dL increased during HCL compared to ST, reaching significance for adolescents and children: HCL 73.7% ± 7.5% vs. ST 68.0% ± 15.6% for adults (P = 0.08), HCL 79.0% ± 12.6% vs. ST 60.6% ± 13.4% for adolescents (P = 0.01), and HCL 69.2% ± 13.5% vs. ST 54.9% ± 12.9% for children (P = 0.003). Conclusions: The Omnipod personalized MPC algorithm was safe and performed well over 5 days and 4 nights of use by a cohort of participants ranging from youth aged ≥6 years to adults with T1D under supervised free-living conditions with challenges, including daily physical activity and unrestricted meals.
format Online
Article
Text
id pubmed-7047109
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-70471092020-02-28 Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions Sherr, Jennifer L. Buckingham, Bruce A. Forlenza, Gregory P. Galderisi, Alfonso Ekhlaspour, Laya Wadwa, R. Paul Carria, Lori Hsu, Liana Berget, Cari Peyser, Thomas A. Lee, Joon Bok O'Connor, Jason Dumais, Bonnie Huyett, Lauren M. Layne, Jennifer E. Ly, Trang T. Diabetes Technol Ther Original Articles Background: The objective of this study was to assess the safety and performance of the Omnipod(®) personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an investigational device. Materials and Methods: A 96-h hybrid closed-loop (HCL) study was conducted in a supervised hotel/rental home setting following a 7-day outpatient standard therapy (ST) phase. Eligible participants were aged 6–65 years with A1C <10.0% using insulin pump therapy or multiple daily injections. Meals during HCL were unrestricted, with boluses administered per usual routine. There was daily physical activity. The primary endpoints were percentage of time with sensor glucose <70 and ≥250 mg/dL. Results: Participants were 11 adults, 10 adolescents, and 15 children aged (mean ± standard deviation) 28.8 ± 7.9, 14.3 ± 1.3, and 9.9 ± 1.0 years, respectively. Percentage time ≥250 mg/dL during HCL was 4.5% ± 4.2%, 3.5% ± 5.0%, and 8.6% ± 8.8% per respective age group, a 1.6-, 3.4-, and 2.0-fold reduction compared to ST (P = 0.1, P = 0.02, and P = 0.03). Percentage time <70 mg/dL during HCL was 1.9% ± 1.3%, 2.5% ± 2.0%, and 2.2% ± 1.9%, a statistically significant decrease in adults when compared to ST (P = 0.005, P = 0.3, and P = 0.3). Percentage time 70–180 mg/dL increased during HCL compared to ST, reaching significance for adolescents and children: HCL 73.7% ± 7.5% vs. ST 68.0% ± 15.6% for adults (P = 0.08), HCL 79.0% ± 12.6% vs. ST 60.6% ± 13.4% for adolescents (P = 0.01), and HCL 69.2% ± 13.5% vs. ST 54.9% ± 12.9% for children (P = 0.003). Conclusions: The Omnipod personalized MPC algorithm was safe and performed well over 5 days and 4 nights of use by a cohort of participants ranging from youth aged ≥6 years to adults with T1D under supervised free-living conditions with challenges, including daily physical activity and unrestricted meals. Mary Ann Liebert, Inc., publishers 2020-03-01 2020-02-21 /pmc/articles/PMC7047109/ /pubmed/31596130 http://dx.doi.org/10.1089/dia.2019.0286 Text en © Jennifer L. Sherr, et al., 2019; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Original Articles
Sherr, Jennifer L.
Buckingham, Bruce A.
Forlenza, Gregory P.
Galderisi, Alfonso
Ekhlaspour, Laya
Wadwa, R. Paul
Carria, Lori
Hsu, Liana
Berget, Cari
Peyser, Thomas A.
Lee, Joon Bok
O'Connor, Jason
Dumais, Bonnie
Huyett, Lauren M.
Layne, Jennifer E.
Ly, Trang T.
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
title Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
title_full Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
title_fullStr Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
title_full_unstemmed Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
title_short Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
title_sort safety and performance of the omnipod hybrid closed-loop system in adults, adolescents, and children with type 1 diabetes over 5 days under free-living conditions
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047109/
https://www.ncbi.nlm.nih.gov/pubmed/31596130
http://dx.doi.org/10.1089/dia.2019.0286
work_keys_str_mv AT sherrjenniferl safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT buckinghambrucea safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT forlenzagregoryp safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT galderisialfonso safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT ekhlaspourlaya safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT wadwarpaul safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT carrialori safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT hsuliana safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT bergetcari safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT peyserthomasa safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT leejoonbok safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT oconnorjason safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT dumaisbonnie safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT huyettlaurenm safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT laynejennifere safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions
AT lytrangt safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions